title: Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.
authors.affiliation: CNRS UMR 5235, Université de Montpellier, Montpellier, France.
authors.forename: A-L
authors.initials: AL
authors.lastname: Gagez
authors.affiliation: INSERM U1058, Université de Montpellier, Montpellier, France.|Département de Bactériologie-Virologie CHRU de Montpellier, Montpellier, France.
authors.forename: E
authors.initials: E
authors.lastname: Tuaillon
authors.affiliation: Département de Bactériologie-Virologie CHRU de Montpellier, Montpellier, France.
authors.forename: R
authors.initials: R
authors.lastname: Cezar
authors.affiliation: Département d'Hématologie Clinique, CHRU de Tours, Tours, France.
authors.forename: C
authors.initials: C
authors.lastname: Dartigeas
authors.affiliation: Département d'Hématologie Clinique, CHRU Nantes, Nantes, France.
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.affiliation: APHP, GHUPSSD, Hôpital Avicenne, Service d'hématologie biologique, Bobigny, France.
authors.forename: R
authors.initials: R
authors.lastname: Letestu
authors.affiliation: Service de médecine onco-hématologie, CHD La Roche sur Yon, La Roche sur Yon, France.
authors.forename: H
authors.initials: H
authors.lastname: Maisonneuve
authors.affiliation: CNRS UMR 7292, Université François Rabelais, CHRU de Tours, France.
authors.forename: V
authors.initials: V
authors.lastname: Gouilleux-Gruart
authors.affiliation: INSERM U1058, Université de Montpellier, Montpellier, France.
authors.forename: K
authors.initials: K
authors.lastname: Bollore
authors.affiliation: Département d'Hématologie Clinique, CHRU Dijon, Dijon, France.
authors.forename: E
authors.initials: E
authors.lastname: Ferrant
authors.affiliation: Centre Paoli Calmette, Marseille, France.
authors.forename: T
authors.initials: T
authors.lastname: Aurran
authors.affiliation: Département d'Hématologie Clinique, CHRU Nancy, Nancy, France.
authors.forename: P
authors.initials: P
authors.lastname: Feugier
authors.affiliation: Centre Henri Becquerel, Rouen, France.
authors.forename: S
authors.initials: S
authors.lastname: Leprêtre
authors.affiliation: CNRS UMR 5235, Université de Montpellier, Montpellier, France.|Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.
authors.forename: G
authors.initials: G
authors.lastname: Cartron
mesh_terms: D000920:Antibody-Dependent Cell Cytotoxicity; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism*; D008297:Male; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics*; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C496124:FCGR3A protein, human; D017452:Receptors, IgG; D016753:Interleukin-10; D000069283:Rituximab